Filing Details
- Accession Number:
- 0000950170-24-030331
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-12 20:24:20
- Reporting Period:
- 2024-03-11
- Accepted Time:
- 2024-03-12 20:24:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 730272 | Repligen Corp | RGEN | Biological Products, (No Disgnostic Substances) (2836) | 042729386 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1733143 | Ralf Kuriyel | C/O Repligen Corporation 41 Seyon St., Bldg 1, Ste 100 Waltham MA 02453 | Senior Vp, R&D | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-11 | 1,271 | $86.10 | 27,777 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-11 | 3,517 | $193.73 | 24,260 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-03-11 | 1,271 | $0.00 | 1,271 | $86.10 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2030-02-27 | No | 4 | M | Direct |
Footnotes
- $193.73 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.64 to $194.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- This option is fully vested and exercisable.
Billionaire Hedge Funds
